This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2002;288:2111.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Senate voted to confirm Mark B. McClellan, MD, PhD, as the new director of the US Food and Drug Administration (FDA). Although he has no regulatory experience, McClellan most recently served as a member of President Bush's Council of Economic Advisors, helping the administration form health care policies.

At his hearing before the Senate Health, Education, Labor, and Pensions Committee, McClellan vowed to speed approval of new drugs and devices while maintaining a commitment to health and safety.

Committee chair Edward Kennedy (D, Mass) expressed concern about McClellan and about the Bush administration stacking FDA advisory panels with "people with questionable credentials." McClellan said that he would never appoint unqualified advisors; he quickly followed that statement by saying that "a diversity of opinions" is needed on the panels.

In a written follow-up question, Kennedy expressed misgivings about the appointment of David Hager, MD, to the FDA's Reproductive . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?